Fluocinolone Acetonide Intravitreal Implant (Retisert)

Covered only for the FDA‑approved indication of chronic non‑infectious uveitis affecting the posterior segment of the eye; active viral, bacterial, mycobacterial, or fungal ocular infection is excluded. Approval requires documentation of the diagnosis and absence of active ocular infection, dosing is limited to the 0.59 mg intravitreal implant (releases ≈0.6 μg/day tapering to ~0.3–0.4 μg/day) and is authorized for up to 30 months.

"Diagnosis of chronic non-infectious uveitis affecting the posterior segment of the eye (required for approval)."

Sign up to see full coverage criteria, indications, and limitations.